6-K filed Aug 20, 2026 at 07:35 ET
Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY), cash burn continues with $14.0M cash on hand funding operations into H2 2027. Pipeline progress includes upcoming 3-year EVX-01 data at ESMO and new preclinical programs (EVX-04, EVX-05, EVX-V1), but the company remains pre-revenue with no near-term catalysts that change the fundamental cash-burn story. A post-period ATM sale of $1.5M adds modest dilution. The combination of steady cash burn, pre-revenue status, and pipeline milestones that are months away suggests limited near-term catalysts for the stock.